In the dynamic landscape of global health, few realms are as intriguing and ever-evolving as the market for psoriasis treatments. Psoriasis, a chronic skin condition affecting millions across the globe, necessitates a robust, innovative, and responsive market to meet its diverse and developing needs. This blog post will delve deep into the latest statistical insights reflecting the current state of the psoriasis market. Through our exploration of market size, emerging trends, key players, and future outlook, we aspire to provide a comprehensive understanding that empowers industry leaders, medical practitioners, and patients alike. Immerse yourself as we unravel the intriguing statistics and facts that are shaping the psoriasis market of today and tomorrow.

The Latest Psoriasis Market Size Statistics Unveiled

The global psoriasis treatment market size was valued at USD 20.41 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 9.8% from 2021 to 2028.

Painting a vibrant financial portrait, the recent valuation of the global psoriasis treatment market at a noteworthy USD 20.41 billion in the year of 2020 gives us a keen insight into the sheer gravity and scale of psoriasis concerns globally. This figure even takes on greater significance, as industry observers foresee the market blossoming at a compound annual growth rate (CAGR) of 9.8% from 2021 to 2028. These trends poignantly underline the intensifying efforts and escalating investment towards addressing the psoriasis challenge, demonstrating not just need but the increasing potency of the psoriasis treatment realm.

By 2027, the Psoriasis Drugs market worldwide is projected to reach US$21.1 Billion, driven by a compounded growth of 7.7%.

The projection that the Psoriasis Drugs market worldwide will skyrocket to US$21.1 Billion by 2027, fueled by a compounded growth of 7.7%, paints a dynamic picture of the industry. Detailed in these figures, one can discern the relentless pace of innovation and commercialization in psoriasis treatments. Moreover, with the rapid growth rate indicated, it’s clear that stakeholders are recognizing and responding to the burgeoning demand for more effective psoriasis drugs. Thus, these projections not only underscore the significance of the market opportunity, but also capture the momentum of advancing medical progress within the field of dermatology. This allows potential investors, pharmaceutical players, and medical professionals to truly gauge the potential and direction of psoriasis therapeutics.

The psoriasis treatment market in Asia-Pacific is expected to grow at the highest CAGR of 9.6% from 2020 to 2027.

Highlighting the expected growth of the psoriasis treatment market in Asia-Pacific demonstrates the market’s dynamism and upward trajectory in that region. With a projected Compound Annual Growth Rate (CAGR) of 9.6% from 2020 to 2027, it indicates substantial opportunities for both existing players and new entrants in this sector. It underscores the escalating demand for these treatments, an aspect that could be attributed to factors such as increasing awareness, prevalence of the condition, or improved accessibility to healthcare services. This statistic thus paints a compelling picture of the market’s future, useful for informing strategic planning and investment decisions within the psoriasis industry.

The biologics segment accounted for almost half of the total share of the psoriasis treatment market in 2019.

Harnessing the power of numbers, it is fascinating to illuminate that in the landscape of psoriasis treatment market in 2019, the biologics segment claimed nearly half of the pie. This hefty share underlines the pivotal role of biologics in the broader narrative of the market, providing a window into contemporary trends in treatment preferences. This statistic paints a vivid picture of the then market composition, which is invaluable for stakeholders aiming to understand the dynamics of the psoriasis market, strategize, and forecast future avenues. Thus, this fact serves as the cornerstone for discussions on market size, growth trajectories, and investment directions in the field of psoriasis treatment.

In North America, the psoriasis market size was valued at USD 8.9 billion in 2020 and is predicted to rise to USD 12.4 billion by 2026, growing at a CAGR of 7.4% during the forecast period.

Highlighting the unprecedented growth of the psoriasis market in North America, this statistic serves as an illuminating beacon in the vast sea of healthcare industry data. It paints a vivid scenario, revealing a landscape where the value permeating from the psoriasis market is in an energetic trajectory upwards – from an impressive USD 8.9 billion in 2020 that is predicted to soar to an even loftier USD 12.4 billion by 2026. With a projected compound annual growth rate (CAGR) of 7.4%, it’s hard not to be awed by the potential of this market during the specified forecast period.

This invaluable information fuels anticipations of future trends in the psoriasis market, guiding investment decisions and informing pharmaceutical marketing strategies. It’s a barometer measuring the industry’s health, showcasing the reality of the market dynamics, and drawing a clearer roadmap to the opportunities that lie ahead. In essence, this statistic is a compass guiding us through the economic landscape of psoriasis treatment, implying a steady incline of patients, treatments, and consequently, potential profits. It draws a picture of an evolving market, which may motivate innovation and competition amongst solution providers, ultimately serving the interests of patients and healthcare providers.

Plaque psoriasis holds the largest share of 85.0% in the global psoriasis treatment market.

Highlighting the dominant stake of plaque psoriasis in the global psoriasis treatment market with an overwhelming 85.0% share provides a compelling map for understanding the terrain of this industry. It’s akin to flashing a high-powered spotlight in an expansive arena, it narrows focus to where most of the action is happening. From the standpoint of a market researcher, pharmaceutical company, or healthcare provider, this data outlines where their attention should be channeled. Potentially, it indicates that the arsenal of treatments addressing plaque psoriasis might require expansion and innovation. Furthermore, the figure is a testament to the prevalence of plaque psoriasis among other types of this skin condition, emphasizing a market need and consequently, opportunities for commercial success.

In the psoriasis drug market, Japan is expected to hold maximum revenue share segment over the forecast period.

Piecing together the intricate puzzle of market size statistics for psoriasis treatments, it’s intriguing to highlight Japan’s anticipated dominant stance in terms of revenue. The profound implications of this forecast extend beyond the borders of this island country. The first obvious ramification is the commercial potential this presents to pharmaceutical companies vying for a prominent stake in the global market. Additionally, this dominance could also be a beacon for innovative remedies, setting the pace and inspiring global advancements in psoriasis treatment. In essence, Japan’s projected superior rank isn’t just a statistic; it’s a crystal ball into the future of psoriasis management worldwide.

The European market for psoriasis treatment is expected to generate significant revenue, with Germany being the highest contributor, due to the high prevalence of the disease in the region.

Highlighting the European psoriasis treatment market’s expected revenue surge underscores the growing economic significance of this sector, while Germany’s leading role illuminates the geographical disparity in disease prevalence. The statistic offers readers a microcosmic view of market trends, enabling them to comprehend the financial magnitude and to strategically analyze European market inclinations. Furthermore, Germany’s contribution underscores the necessity for increased focus and resource allocation to manage the disease in high prevalence regions, thus intertwining market dynamics with public health decisions. Such geographic-specific intelligence forms the cornerstone of informed investment and policy-making in the pharmaceutical industry.

By 2027, the UK market for psoriasis treatment is expected to reach about $566.0 million.

Foreseeing the scope of the UK psoriasis treatment market can serve as a guiding star for stakeholders. Indeed, this prophecy of reaching a worth of approximately $566.0 million by 2027 is a substantial indication of the immense potential. It not only reflects the anticipated expansion of the market but also provides a perspective on the gravity of psoriasis as a health concern that warrants significant medical and therapeutic attention. Besides, investors and dugs manufacturing companies can derive key insights from this projected figure, enabling them to strategize their moves accordingly for maximizing their market share in the burgeoning industry. Lastly, this statistic unmistakably underscores the vital need for innovation and investment in therapeutic research and development for psoriasis treatment, promising a brighter future for affected individuals.

The systemic segment contributed to the largest market share in 2020, accounting for around 73% of the global psoriasis treatment market.

Interpreting market statistics can sometimes feel like reading tea leaves, but the significance of the systemic segment claiming approximately 73% of the global psoriasis treatment market in 2020 is akin to a neon sign illuminating essential trends and patterns. It’s like discovering a celebrity at a party – drawing the lion’s share of attention and dictating the flow of the evening. This commanding presence of the systemic segment not only underscores its towering influence in present times but also teases potential narratives about future psoriasis treatment market movements. It’s like standing at a vantage point, getting a bird’s eye view of the vast landscape of opportunities and strategies in psoriasis care. This statistic, in essence, serves as a compass for key stakeholders navigating the robust, dynamic, and ever-evolving world of psoriasis treatment options.


In summary, the psoriasis market continues to grow and evolve, offering numerous opportunities for businesses operating in this sector. As the prevalence of psoriasis increases globally, so does the demand for effective treatments and management solutions. Understanding these market size statistics can immensely aid stakeholders, medical companies, and investors who want to make informed decisions and strategic plans. Therefore, staying abreast of the psoriasis market’s constant changes is pivotal for any businesses aiming to thrive in this healthcare sphere. As science and technology advance, it promises to create further efficiency, cost savings, and improved treatments, all of which would contribute to the expansion of the psoriasis market.


0. –

1. –

2. –

3. –

4. –

5. –

6. –

7. –

8. –